Off-Pump Coronary Artery Bypass Device Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Positioner devices, and Stabilizer Devices

Global Off-Pump Coronary Artery Bypass Device Market Report to 2032

The global off-pump coronary artery bypass (OPCAB) device market was valued at $219 million in 2025. It is expected to decrease at a compound annual growth rate (CAGR) of -1.2%, reaching $200 million by 2032.

This report covers the global market for OPCAB devices, including stabilizer devices and positioner devices used during beating-heart coronary artery bypass procedures.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032 and historical data back to 2022.

Although the market is expected to decline, specialized device use and higher pricing in complex cases are expected to partially offset falling procedure volumes. Clinical benefits, reduced costs and selected patient suitability continue to support demand, while procedural difficulty and surgeon preference for ONCAB limit broader adoption.

Market Overview

The global OPCAB device market includes devices used during coronary artery bypass grafting procedures performed without a cardiopulmonary bypass pump.

OPCAB procedures are performed while the heart is still beating. Because the surgical field is moving, specialized stabilizers and positioners are required to help surgeons access target vessels and perform precise anastomoses.

The market is segmented into stabilizer devices and positioner devices. Stabilizers help reduce movement at the surgical site, while positioners assist in manipulating and exposing the heart during the procedure.

Overall procedure volumes are expected to remain under pressure as many cardiac surgeons continue to prefer on-pump coronary artery bypass (ONCAB) procedures. However, OPCAB remains clinically relevant in selected patient populations and complex cases where avoiding cardiopulmonary bypass may offer important benefits.

Market Drivers

Clinical Benefits of OPCAB

Patients who undergo OPCAB procedures may experience reduced rates of bleeding, neurocognitive effects, kidney complications and shorter hospital stays.

These benefits are primarily linked to the fact that a cardiopulmonary bypass pump is not used. Avoiding extracorporeal circulation can reduce some of the risks associated with exposing blood to artificial surfaces during ONCAB procedures.

These clinical advantages help slow the shift away from OPCAB and support continued device use in patients who may benefit from a beating-heart approach.

Although the total market is expected to decline, these benefits preserve a base level of demand for stabilizers and positioners in selected cardiac surgery programs.

Reduced Cost

OPCAB procedures can be less expensive than ONCAB procedures because the costly devices used during cardiopulmonary bypass are not required.

Patients may also recover more quickly after OPCAB procedures, which can reduce hospital costs associated with longer stays or additional post-operative management.

Hospitals that are focused on cost control may continue to favor OPCAB in appropriate cases, especially when clinical outcomes are comparable and patient anatomy supports the technique.

This cost advantage supports ongoing use of OPCAB devices, even as overall procedure growth remains constrained.

Specialized Device Use in Complex Cases

Despite declining procedure volumes, pricing dynamics are expected to partially offset market pressure.

In certain patient risk classes, OPCAB procedures may remain comparable to less invasive alternatives based on anatomical suitability and long-term outcomes. As a result, physicians may continue to select OPCAB for specific cases.

Specialized stabilizers and positioners are especially important in complex procedures, where precise exposure and stabilization are required.

The use of higher-priced devices in these cases is expected to support market value, even as overall procedure numbers decline.

Market Limiters

Inherent Procedural Difficulties

An OPCAB procedure is significantly more difficult to perform than an ONCAB procedure.

During OPCAB, the patient's heart is beating while the surgeon performs delicate anastomosis on a target vessel, which can be as narrow as 1 mm in internal diameter. This movement creates major technical challenges.

Surgeons are also often required to place a partially occluding clamp on the aorta to allow hand suturing of the proximal end of the graft anastomosis. As a result, even OPCAB patients may still face some adverse effects associated with aortic clamping.

Although anastomosis assist devices can help address this problem, their penetration rate within OPCAB procedures remains relatively low.

Surgeon Preference for ONCAB

Many physicians continue to prefer ONCAB when performing CABG procedures.

Surgeons may be reluctant to transition to OPCAB because it requires additional training and demands more technically challenging surgical techniques. This is particularly relevant among surgeons who have used ONCAB for most of their careers.

ONCAB provides a motionless and bloodless surgical field, which many surgeons view as more predictable for graft placement and suturing.

This preference for ONCAB continues to limit OPCAB adoption and is expected to impede stronger growth over the forecast period.

Declining and Moderating Procedure Demand

OPCAB device demand is closely tied to procedure volume.

As cardiac surgery patterns evolve and alternative treatment options continue to develop, overall demand for OPCAB procedures remains under pressure. The market is therefore constrained by both procedure decline and limited conversion from ONCAB.

Even where OPCAB has clinical advantages, adoption depends heavily on surgeon training, confidence and institutional practice patterns.

As a result, market value is expected to decline modestly despite the use of specialized devices and higher pricing in selected cases.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
• Time frame: Base year 2025, forecasts to 2032 and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, device utilization assumptions and forecast trends.
• Device scope: The report covers off-pump coronary artery bypass devices segmented into stabilizer devices and positioner devices.

Markets Covered and Segmentation

Off-Pump Coronary Artery Bypass Device Market

• Device type: Stabilizer devices and positioners.

Stabilizer devices are used to reduce movement at the coronary target site during beating-heart CABG. These devices are essential to OPCAB procedures because they help create a more stable field while the heart continues to beat.

Positioner devices are used to lift, rotate or expose the heart so surgeons can access target vessels. These products support procedural visibility and improve access during complex grafting procedures.

Together, stabilizers and positioners allow surgeons to perform CABG without placing the patient on cardiopulmonary bypass. This makes them core device categories in the OPCAB market.

Because OPCAB procedures are technically demanding, product performance, ease of use, reliability and surgeon familiarity are important competitive factors.

The market is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold and average selling prices.

Competitive Analysis

Medtronic was the leading competitor in the global OPCAB market.

For stabilizers, Medtronic offers its Octopus(TM) Evolution, Octopus(TM) 4 and Octopus(TM) 4.3 tissue stabilizers. These products are used to stabilize the surgical field during beating-heart procedures.

The company's heart positioner portfolio includes Starfish(TM) Evo, Starfish(TM) 2, Urchin(TM) and Urchin(TM) 2. These devices complete Medtronic's OPCAB product offering across stabilization and positioning.

Since Medtronic has left the ventricular assist device market, it is expected that the company will expand its presence in the OPCAB segment. Its established cardiac surgery portfolio and broad global presence support its leadership in this market.

Getinge was the second-leading competitor in the global OPCAB market.

The company offers beating-heart stabilizers and positioners as part of its broader cardiac surgery product portfolio. Getinge participates across multiple segments and has shifted investments toward other areas.

Because the OPCAB market is declining, Getinge is expected to lose some market share in the coming years. However, its existing product base and established hospital relationships support continued participation.

Terumo captured the third-leading position in the total OPCAB market.

The company's Universal Stabilizer Arm(TM) introduced the concept of an articulating arm attached to a sternal retractor for cardiac surgery applications.

With a unique and innovative product portfolio, Terumo is likely to gain greater presence in the OPCAB market over the forecast period, particularly as customers seek reliable stabilization solutions for selected beating-heart procedures.

Technology and Practice Trends

Beating-Heart Surgery

OPCAB procedures are designed to avoid the use of cardiopulmonary bypass.

This approach remains important for selected patients who may benefit from avoiding extracorporeal circulation.

Stabilization Technology

Stabilizer devices are central to OPCAB procedure success.

Improved stabilization helps surgeons perform more precise grafting on a moving heart.

Heart Positioning Systems

Positioners support access to coronary vessels during beating-heart surgery.

These devices help improve exposure and allow surgeons to work across different target areas.

Cost-Focused Cardiac Surgery

OPCAB can reduce certain procedural costs by avoiding cardiopulmonary bypass equipment.

This supports continued interest among hospitals seeking lower-cost surgical approaches in appropriate patients.

Selective Patient Use

OPCAB is increasingly tied to selected patient profiles rather than broad CABG adoption.

Anatomical suitability, surgeon preference and patient risk factors influence whether OPCAB is chosen.

Pricing Support from Specialized Devices

Although procedure volumes are expected to decline, higher-priced specialized devices can support market value.

Complex OPCAB procedures may require advanced stabilizers and positioners, helping offset some volume pressure.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global OPCAB device market today, and how much is it expected to change through 2032?
• How are stabilizer devices and positioner devices performing across the forecast period?
• Why is the overall OPCAB device market expected to decline?
• How are higher device prices and specialized product use offsetting procedure volume pressure?
• Which patient and procedure types continue to support OPCAB use?
• How do OPCAB procedures compare with ONCAB in terms of clinical benefits and cost?
• Why do procedural difficulty and training requirements limit adoption?
• How does surgeon preference for ONCAB affect the outlook for OPCAB devices?
• Which companies lead the global OPCAB device market?
• How are Medtronic, Getinge and Terumo positioned across stabilizers, positioners and beating-heart surgery platforms?

The Global Off-Pump Coronary Artery Bypass Device Market Report from iData Research answers these questions with procedure-based models, ASP data, company share insights and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand OPCAB procedure trends and support commercial planning in the global OPCAB device market.